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A B S T R A C T
Objective: To study the agreement among three distinct criteria for metabolic syndrome 
(MS) adapted to adolescents, and to identify associated factors for MS.
Methods: Cross-sectional study with 65 obese subjects aged 10 to 18 years, attended to at 
the Outpatient Clinic for Obese Children and Adolescents at the Clinical Hospital of the 
Universidade Estadual de Campinas (Unicamp). MS was defined using the criteria of the 
World Health Organization (WHO), the International Diabetes Federation (IDF), and the 
Adult Treatment Panel III (ATP III). Clinical, anthropometrical, and laboratorial data were 
associated to MS.
Results: From the 65 subjects, none had MS according to the WHO criteria, while 18 were 
diagnosed with MS (27.6%) according to the IDF, and 19 (29.2%) according to the ATP III. 
Agreement between IDF and ATP III was excellent (kappa 81%). In this study, puberty and 
triglycerides levels showed significant statistical difference when comparing subjects with 
and without MS, the first for ATP III (p = 0.03), and the second for IDF (p = 0.005) and ATP III 
(p = 0.001) criteria.
Conclusion: The WHO criteria does not seem to be adequate for adolescents. IDF  and ATP 
III criteria had an excellent agreement. Puberty and triglycerides were associated with MS.
 ☆Study conducted at the Outpatient Clinic for Obese Children and Adolescents, Universidade Estadual de Campinas, Campinas, SP, Brazil 
 *Corresponding author at: Rua Botafogo, 151/149, Campinas, SP, 13130-601, Brazil 
 E-mail address: mzambon@fcm.unicamp.br (M.P. Zambon) 
0104-4230 © 2013 Elsevier Editora Ltda. 
Síndrome metabólica em adolescentes obesos: o que é suficiente?
R E S U M O
Objetivo: Avaliar a correlação de três critérios de síndrome metabólica (SM) para adolescentes 
e identificar fatores associados.
Métodos: Estudo transversal com 65 pacientes obesos entre 10 e 18 anos do Ambulatório 
de Crianças e Adolescentes Obesos do HC-Unicamp. SM foi definida de acordo com a 
Organização Mundial da Saúde (OMS), International Diabetes Federation (IDF) e Adult 
Treatment Panel III (ATP III). Buscaram-se fatores associados a SM em dados clínicos, 
antropométricos e laboratoriais.
Resultados: Dos 65 pacientes, nenhum foi diagnosticado como SM pela OMS, sendo 18 
(27.6%) pelo IDF e 19 (29.2%) pelo ATP III. A correlação entre IDF e ATP III foi excelente 
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(kappa 81%). Neste estudo, a puberdade e os triglicérides apresentaram diferença 
estatisticamente significativa entre pacientes com e sem SM, sendo a primeira para o 
ATP III (p = 0.03) e o segundo para IDF (p = 0.005) e ATPIII (p = 0.001).
Conclusão: O critério da OMS não parece ser adequado para adolescentes. Há correlação 
excelente entre os critérios do IDF e ATP III. Puberdade e triglicérides foram fatores 
associados à SM.
Introduction
The childhood obesity epidemic is followed closely by early 
onset of diseases once just observed in adults, such as diabetes 
mellitus type 2, high blood pressure, impaired lipid profile, 
and cardiovascular diseases.1–3 The clustering of risk factors 
for these diseases is called metabolic syndrome (MS), which 
is highly prevalent in adults nowadays, and has serious 
consequences on life expectancy.4–8
The diagnosis of MS in the pediatric field still has not 
reached a consensus in the literature, since it is difficult to 
define reference levels for several components such as insulin 
resistance and lipid levels according to age.6,8–11 MS diagnosis 
aims to detect patients at risk for cardiovascular and metabolic 
diseases, allowing the development of a preventive measures 
and treatment when needed.10
The first MS criteria was presented in 1998 by the World 
Health Organization (WHO), with emphasis on risk factors 
for diabetes mellitus type 2.12 In 2001, the Adult Treatment 
Panel III (ATP III) presented an MS definition focused on 
cardiovascular diseases.13 Finally, in 2007, the International 
Diabetes Federation (IDF) developed a criteria that addressed 
to children aged 10 and older.14
Longitudinal studies have demonstrated that adults 
presenting MS started their health problems during childhood, 
thus justifying the investigation of MS risk factors in 
children.15,16
MS criteria for children and adolescents usually are an 
adaptation of the adult criteria. In the search for an alternative, 
criteria have been developed specifically for the pediatric 
group, such as the use of a continuous score from childhood 
until adulthood,7 and a proposal considering components 
which are early risk factors, such as birth weight and family 
history.17
Of the MS components, insulin resistance is believed to have 
a central role on metabolic dysfunction, leading to problems 
such as hyperlipidemia, hepatic steatosis, and atherosclerosis, 
which may progress to cardiovascular diseases and diabetes 
mellitus type 2.18,19
Obese children and adolescents frequently present insulin 
resistance as a consequence of a primary reduction in insulin 
sensitivity and a subsequent increase in production.19
Reference levels for insulin resistance are still not 
determined for pediatric and adolescents patients, but they 
are known to be influenced by ethnicity and puberty.20,21 
The Homeostatic Model Assessment for Insulin Resistance 
(HOMA-IR), a relation between fasting glucose and insulin, has 
been recognized as the most sensitive and specific method for 
measuring insulin resistance.20
The present study aimed to evaluate the prevalence of MS 
and the agreement between three distinct definitions (WHO, 
IDF, ATP III). In addition, the study aimed to individually 
analyze associated clinical and laboratorial factors of obese 
adolescents on follow-up at an outpatient clinic from a tertiary 
university hospital.
Methods
This is cross-sectional study; data was collected between 
April, 2005 and January, 2010 from 150 subjects who presented 
consecutively at the Outpatient Clinic for Obese Children 
and Adolescents at the Clinical Hospital of the Universidade 
Estadual de Campinas (Unicamp). Selected subjects presented 
age between 10 and 18 and obesity (body mass index [BMI] 
> 95th percentile).22 Exclusion criteria were impaired 
neurological development (which could be related to a genetic 
syndrome), hepatic or kidney dysfunction, and endocrine 
diseases such as hypothyroidism. 
Data was collected from patients’ history (age, gender, 
family-reported age since excessive weight gain started), 
physical examination (pubertal development, presence of 
acanthosis nigricans, blood pressure), anthropometrical 
measures (weight, height, abdominal circumference), and 
laboratory analysis. Puberty was determined when Tanner 
stage ≥ 2.23 Weight and height measures were obtained as 
described by Cameron,24 from which BMI was calculated. 
Abdominal circumference was obtained according to 
Freedman’s methods,25 and McCarthy’s curves were used as 
reference.26
Blood pressure was measured according to the guidelines of 
the Second Task Force on Blood Pressure Control in Children. 
High blood pressure (BP) was considered if systolic blood 
pressure (SBP) and/or diastolic blood pressure (DBP) ≥ 95th 
percentile, according to age, gender, and height percentile.27
Serum fasting glucose, insulin, triglycerides (TGC), 
total-cholesterol, high-density lipoprotein- (HDL) cholesterol, 
and low-density lipoprotein- (LDL)cholesterol concentrations 
were measured using the methodology established by the 
Clinical Pathology Laboratory of Unicamp. HOMA-IR was 
calculated by the formula: fasting glucose (mg/dL) x fasting 
insulin (μU/mL) /405.28
Considering the lipid reference levels used by IDF for children, 
the MS definitions by WHO and ATP III were adapted using the 
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same levels: TGC were considered abnormal when ≥ 150 mg/dL, 
and HDL-cholesterol when < 40 mg/dL, for both genders.
To adapt the WHO criteria for children, it was decided 
to keep the proportionality of what is proposed for adults: 
glucose levels unchanged, BMI value for children when defines 
obesity and blood pressure that characterize hypertension. The 
waist to hip ratio was changed for waist circumference, and 
microalbuminuria was not evaluated (Box 1). 
On the ATP III criteria, the proportionality was also kept: 
no change on glucose levels, blood pressure levels for pre-
Box 1 – Adapted metabolic syndrome criteria.
Adapted metabolic syndrome definition from the World 
Health Organization
Patient must have at least one of the following:
r Diabetes mellitus – fasting glucose ≥ 126mg/dL or 2h after 
75g glucose challenge ≥ 200mg/dL
r Impaired glucose tolerance – fasting glucose < 126mg/dL and 
2h after 75g glucose challenge ≥ 140mg/dL and < 200mg/dL
r Impaired fasting glucose – fasting glucose ≥ 110mg/dL and  
< 126mg/dL and 2h after 75g glucose challenge < 140mg/dL
r Insulin resistance – under hyperinsulinemic, euglycemic 
conditions, glucose uptake below lowest quartile for 
background population under investigation.
And any two or more of the following:
r Waist circumference > 95th percentile26 and/or BMI > 95th 
percentile;22
r Triglycerides ≥ 150mg/dL and/or HDL cholesterol < 40 mg/dL;
r Blood pressure ≥ 95th percentile;27
Adapted metabolic syndrome definition from the Adult 
Treatment Panel III
Any three of the following:
r Fasting glucose ≥ 110 mg/dL;
r Waist circumference > 95th percentile;26
r Triglycerides ≥ 150mg/dL;
r HDL cholesterol < 40mg/dL;
r Blood pressure between 90th and 95th percentiles;27
Metabolic syndrome definition from the International 
Diabetes Federation
Age 6 to younger than 10 years: cannot be diagnosed; 16 years or 
older: adult criteria.
From 10 to 16 years old:
r Obligatory component: abdominal circumference ≥ 90th 
percentile for age26
r Presence of two or more:
r Triglycerides ≥ 150 mg/dL
r HDL cholesterol < 40 mg/dL
r Systolic blood pressure ≥ 130 mmHg or diastolic 
≥ 85 mmHg27
r Fasting glucose ≥ 100 mg/dL
BMI, body mass index; HDL, high-density lipoprotein.
hypertension (between the 90th and 95th percentiles). Waist 
circumference was normal when < 95th percentile for age and 
gender. No adaptation was made for IDF III (Box 1).
In this study, an individual analysis of clinical and 
laboratorial factors related to the presence of MS was proposed, 
including those used by different MS criteria. 
Statistical analyses were performed using the Statistical 
Package for the Social Sciences (SPSS) version 16.0 (SPSS Inc. – 
Chicago, IL, USA). The agreement between MS definitions was 
obtained by the kappa test. The chi-squared test, Fisher’s exact 
test, and and Student’s t-test were used to compare groups and 
risk factors. Significant levels were considered when p < 0.05.29
This study was approved by the Ethics Committee of the 
Medical Sciences Faculty of Unicamp (number 711/2009), and 
an informed consent was obtained from all subjects and their 
parents.
Results
Of the 65 subjects selected, none fulfilled the adapted 
WHO criteria for MS. Using adapted IDF and ATP III criteria, 
18 (27.6%) and 19 (29.2%) were identified with MS, respectively. 
The overall kappa value for these two definitions was 
81% (Table 1).
Gender (IDF: p = 0.30; ATP III: p = 0.46) (Table 2), age (medians 
over 11.5 years; IDF: p = 0.613; ATP III: p = 0.93), family-reported 
age when the excessive weight gain started (medians over 4 
years old; IDF: p = 0.79; ATP III: p = 0.38), and years of obesity 
(medians over 6.8 years; IDF: p = 0.31; ATP III: p = 0.82) were not 
statistically different for MS by both criteria (Table 3). 
Elevated BMI results (median over 32 kg/m2; IDF: p = 0.68; 
ATP III: p = 0.85), BMI z scores (median over +2.3; IDF: p = 0.31; 
ATP III: p = 0.09), and waist circumference (median over 101.7 
cm; IDF: p = 0.48; ATP III: p = 0.23) were found for all patients, 
but with no statistically difference to MS by IDF and ATP III 
adapted criteria (Table 3).
The presence of puberty was statistically different for MS 
according to ATP III adapted criteria (p = 0.03), and close to a 
significant level according to IDF criteria (p = 0.06). Acanthosis 
nigricans (IDF: p = 0.10; ATP III: p = 0.58) was not considered 
an associated factor for MS by both criteria (Table 2). Also, no 
statistically significant difference was found when evaluating 
glucose metabolism using fasting glucose (IDF: p = 0.81; 
ATP III: p = 0.53), insulin (IDF: p = 0.07; ATP III: p = 0.13), and 
HOMA-IR (IDF: p = 0.09; ATP III: p = 0.14). Medians for fasting 
Table 1 – Agreement between metabolic syndrome 
diagnosis by IDF and ATP III.
IDF kappa
Yes No
ATP III 81%
Yes 16 3
No 2 44
IDF, International Diabetes Federation; ATP III, Adult Treatment 
Panel III; kappa – kappa test.
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insulin levels were in the upper level (medians over 19 mg/dL, 
reference for adults up to 20 mg/dL) for subjects with and 
without MS (Table 3).
Blood pressure analysis was made based on medians of 
systolic and diastolic blood pressure. The SBP did not show 
statistically significant difference for MS (IDF: p = 0.31; ATP III: 
p = 0.47), as well as the DBP measures (IDF: p = 0.40; ATP III: 
p = 0.68) (Table 3).
When evaluating lipid profile results, there was no 
statistically significant difference between groups for total 
cholesterol (IDF: p = 0.31; ATP III: p = 0.72), HDL (IDF: 0.34; ATP 
III: p = 0.23), and LDL-cholesterol (IDF: p = 0.38; ATP III: p = 0.63) 
levels. Statistically significant differences for TGC levels were 
found between obese children with and without MS, using both 
adapted ATP III and IDF definitions. Children evaluated for MS 
by IDF presented median TGC levels of 172.44 mg/dL (‘Yes’ 
group) and 96.68 mg/dL (‘No’ group), p = 0.005. Under the ATP 
III adapted criteria median TGC levels were 163 mg/dL (‘Yes’ 
group) and 98.93 mg/dL (‘No’ group), p = 0.001 (Table 3). 
Discussion
Despite the controversy on the need of MS criteria for children 
and adolescents, this study shows MS prevalence on the 
selected subjects using three different criteria from world-
recognized organizations.
None of the patients fulfilled the adapted WHO criteria 
because they did not present a dysfunctional glucose 
metabolism, considered essential for the classification. 
Other studies have showed an MS prevalence ranging from 
5.2%10 to 39%,30 depending on the adaptations made, but 
none of these studies kept impaired glucose or insulin level 
as an obligatory criteria. Based on the data found, it appears 
that the WHO criteria is not a very useful definition for the 
pediatric population, as it considers the presence of impaired 
glucose metabolism, a dysfunction known to happen later 
in life. Patients were probably classified as not having MS as 
consequence of lack of time to develop the impaired laboratory 
findings. With adapted IDF and ATP III = criteria, the prevalence 
found was 27.6% and 29.2%, respectively. When compared 
with studies based on the same criteria and obese pediatric 
population, the data are similar, ranging between 31%30 and 
31.9%21 for IDF and 25.8%10 and 28.7%1 for ATP III.
The agreement between these two criteria was excellent 
(kappa test 81%). Unfortunately, they are not comparable to 
other references, since the criteria used were distinct (ATP III 
and Weiss, kappa test 53%),31 and the selected population was 
not the same: adolescents evaluated using two adult criteria, 
kappa 41%.32
Many studies have shown that child and adolescent obesity 
continues into adulthood,1 and also has a positive association 
with adult cardiovascular and metabolic diseases.33 Although 
MS is defined as a cluster of risk factors for cardiovascular 
and metabolic diseases,1 in this study MS associated factors 
were considered individually, from clinical characteristics to 
laboratorial findings, including those that are usually employed 
to define several MS criteria, such as waist circumference, 
blood pressure, fasting glucose, and lipid profile.  
Younger children are expected to present lower prevalence 
of MS and less risk factors than older children and adolescents. 
This may happen as a consequence of a time-related exposure 
to factors such as hypercaloric diets and sedentary lifestyle.4 
On the contrary, the present study could not find an association 
between MS defined by IDF and ATP III’s adapted criteria 
related to age, family-reported age when excessive weight gain 
started, and years of obesity.
In the same way, there was no association between gender 
and MS in both criteria. Conflicting data exist on this subject, 
since there are publications showing higher frequencies of 
MS in males,1 others showing a slightly higher prevalence 
in females or, as in the present work, showing no significant 
difference according to gender.31 
When considering anthropometric data, BMI and BMI z 
scores, the patients included in this study did not present these 
components as associated factors for MS. However, it is an 
important fact that the medians for all patients were extremely 
high (BMI over 32 kg/m2, and BMI SD scores over +2.3).
Table 2 – Analysis of gender, puberty, and acanthosis nigricans as risk factors for metabolic syndrome by IDF and ATP 
III criteria.
IDF ATP III
Yes No Total p Yes No Total p
Gender
Female 22 11 33 0.30a 22 11 33 0.46a
Male 25 7 32 24 8 32
Puberty
Yes 30 14 44 0.06b 28 16 44 0.03b,c  
No 13 1 14 13 1 14
AN
Yes 31 8 39 0.10a 28 11 39 0.58a
No 10 7 17 12 5 17
IDF, International Diabetes Federation; ATP III, Adult Treatment Panel III; AN, acanthosis nigricans.  
aChi-squared test;
bFisher’s exact test; 
c significance: p > 0.05.
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Table 3 – Distribution of median and standard deviation clinical and laboratorial data according to metabolic syndrome 
criteria by IDF and ATP III.
IDF ATP III
n Median SD p n Median SD p
Age
No 47 11.55 2.18 0.613 46 11.70 2.14 0.931
Yes 18 11.89 1.87 19 11.53 2.01
Age of onset
No 43 4.65 3.16 0.791 42 4.79 3.21 0.388
Yes 17 4.65 3.10 18 4.33 2.95
Years of obesity
No 43 6.86 3.23 0.318 42 6.88 3.41 0.826
Yes 17 7.11 3.83 18 7.05 3.40
BMI
No 47 32.34 6.36 0.689 46 32.71 6.52 0.859
Yes 18 33.32 5.64 19 32.38 5.27
BMI z score
No 36 2.35 0.28 0.315 34 2.35 0.27 0.091
Yes 13 2.38 0.33 15 2.36 0.34
WC
No 47 103.52 14.39 0.484 46 103.96 14.81 0.235
Yes 17 102.86 11.72 18 101.78 10.28
Fasting glucose
No 47 84.43 7.16 0.811 46 84.87 6.94 0.534
Yes 17 84.24 6.36 18 83.11 6.85
Insulin
No 41 19.13 15.51 0.077 41 19.07 15.33 0.133
Yes 15 19.11 7.71 15 19.28 8.68
HOMA-IR
No 41 4.15 3.81 0.092 41 4.16 3.79 0.143
Yes 15 3.98 1.61 15 3.96 1.74
SBP
No 47 116.94 15.56 0.311 46 116.87 15.44 0.478
Yes 18 119.17 12.86 19 119.21 13.36
DBP
No 47 77.06 9.65 0.404 46 77.43 9.87 0.682
Yes 18 77.50 10.88 19 76.58 10.28
TGC
No 47 96.68 34.46 0.005* 46 98.93 37.14 0.001*
Yes 18 172.44 64.4 19 163.00 67.77
Total-cholesterol
No 47 161.89 33.16 0.312 46 162.43 34.14 0.725
Yes 18 163.33 36.77 19 161.95 34.28
HDL-cholesterol
No 47 46.57 9.66 0.342 46 46.83 9.68 0.238
Yes 18 36.33 6.80 19 36.26 6.36
LDL-cholesterol
No 47 99.74 29.45 0.386 46 99.67 29.96 0.635
Yes 18 94.83 40.72 19 95.26 39.26
IDF, International Diabetes Federation; ATP III, Adult Treatment Panel III; BMI, body mass index; WC, waist circumference; HOMA-IR, homeostatic 
model assessment for insulin resistance; SBP, systolic blood pressure; DBP, diastolic blood pressure; TGC, triglycerides; p, Student’s t-test; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein.
* significance: p > 0.05.
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Abdominal circumference measurements were also not 
identified as an associated factor for MS, but all patients 
presented elevated medians as well. Waist circumference 
is a well accepted marker for assessing risk of underlying 
pathologies in adults; however, in the pediatric field it is 
still not a widespread, compulsory part of the examination, 
even with references demonstrating the advantages and high 
sensitivity of this method in screening for patients at risk.26,34
The problem of relating MS criteria and reference values 
for children and adolescents is a recurrent subject,8,11 and 
involves the unsolved question of the influence of the 
physiological changes of puberty. Puberty is a transition period 
with rapid changes occurring in metabolic systems including 
hormonal regulations, changes in body fat and its distribution, 
and reduction in insulin sensitivity.35 This resistance leads 
to an increased insulin secretion, and when associated with 
obesity-related changes in glucose metabolism, could result in 
a increased risk for MS.21,35 The present study has found that 
the presence of puberty was an associated factor for MS using 
ATP III’s adapted criteria (p = 0.03) and an almost significant 
level for IDF’s criteria (p = 0.06). But there are confounding 
factors that must be considered before establishing an 
association between puberty and MS, one of which would be 
the evaluation of insulin resistance.
Acanthosis nigricans is a clinical sign with strong relation 
to hyperinsulinemia risk. It is believed that this cutaneous 
finding can be prior to laboratorial changes such as impaired 
insulin, fasting glucose, or lipids levels, as well as the diagnosis 
of MS.36,37 The presence of acanthosis nigricans in patients 
included in this study was not associated to MS. 
Insulin has a central role on signaling body fat stores 
and energy homeostasis, and also in the clustering of 
cardiovascular risk factors. Insulin resistance is commonly 
associated with obesity, and HOMA-IR is a sensitive and 
specific method for its measurement.20 The present study 
has also showed a tendency to associate MS with insulin 
(IDF: p = 0.07; ATP III: p = 0.13) and HOMA-IR (IDF: p = 0.09; ATP 
III: p = 0.14), although all groups had insulin medians at the 
upper reference level. It is hard to affirm whether the HOMA-IR 
medians found are within normal range, since several cut-off 
points have been proposed for children and adolescents.18 It 
has been recently discussed that the MS diagnosis for pediatric 
patients is probably limited due to the dichotomization of the 
criteria chosen. Very often, obese children and adolescents 
present altered values that are not yet considered abnormal.
Besides acting as the central regulator of glucose, insulin 
also plays an important role on lipid homeostasis. It has long 
been known that there is a highly significant relation among 
insulin resistance, compensatory hyperinsulinemia, and 
hypertriglyceridemia.6 Insulin has three main influences on 
lipids: it enhances triglyceride synthesis in liver and adipose 
tissues, it increases the breakdown of circulating lipoproteins 
by stimulating lipase activity in adipose tissue, and it suppresses 
lipolysis in adipose tissue and muscles.20 The presence of obesity, 
visceral body fat, and insulin resistance, and the consequent 
finding of an impaired lipid profile is well known.38 When 
analyzing the selected patients, there was indeed a significant 
difference on TGC levels between patients with and without MS 
on both criteria used (IDF: p = 0.005, ATP III: p = 0.001).
The finding of TGC as an associated factor for MS is 
congruent with the report by Morrison in a long follow-up 
study, where a significant association of high TGC retained 
from childhood to adulthood with young adult cardiovascular 
disease (CVD) was found. In that study, the authors speculate 
that the association of high TGC from childhood through 
adulthood with adult CVD could reflect the presence of a 
pediatric MS, a known predictor of adult CVD.39
The same did not occur with other lipids (total cholesterol, 
LDL-cholesterol, and HDL-cholesterol). These findings are 
in agreement with the described lipids’ pathophysiology 
secondary to obesity. Over successive cohorts, an increase in 
TGC levels and a reduction in HDL-cholesterol levels has been 
observed as an initial finding. In contrast, total cholesterol, 
LDL-cholesterol, and glucose levels remained unchanged.38
The relation between high blood pressure, lipoprotein 
abnormalities, and insulin resistance is not completely 
understood; it appears to be more complex than any of the 
other components of metabolic syndrome.6 Hypertension is 
a well-recognized CVD risk factor, but the understanding of 
its connection with insulin metabolism is under study. There 
is already evidence showing that patients with essential 
hypertension are insulin resistant and hyperinsulinemic;6 a 
follow-up study has demonstrated that children with high 
blood pressure and TGC who retained these into adulthood 
were more likely to develop diabetes mellitus type 2.39 Even 
with the theoretical connection between hypertension, 
insulin resistance, CVD and, in consequence, MS, the patients 
evaluated in this study did not present high blood pressure 
as an associated factor for MS.
The limitations of this study were its cross-sectional 
design, the relatively small number of patients that were 
classified by MS definitions, and also the fact that the 
adolescents included were referred to a tertiary university 
hospital, thus they were expected to be a homogenously 
severe obese group.
In summary, even with all discussion over MS criteria 
and its usefulness , this study found that the WHO criteria is 
probably not adequate for an early detection of adolescents 
with metabolic risk. However, there is a very good agreement 
between IDF and ATP III criteria in detecting the pediatric 
population with MS. In addition, TGC levels were able to 
identify adolescents that are clearly at risk for early-onset 
metabolic and cardiovascular diseases. Even when not 
fulfilling criteria for MS, these patients need strong preventive 
measures aimed at stopping obesity evolution and avoiding 
clustering health problems.40
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